Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis.

Humans Norfloxacin / therapeutic use Anti-Bacterial Agents / therapeutic use Rifaximin Liver Cirrhosis / complications Quinolones
Norfloxacin Primary prophylaxis Rifaximin Second prophylaxis Spontaneous bacterial peritonitis

Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
28 Aug 2023
Historique:
received: 14 06 2023
accepted: 22 08 2023
medline: 31 8 2023
pubmed: 29 8 2023
entrez: 28 8 2023
Statut: epublish

Résumé

Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in patients with advanced cirrhosis. Prophylactic Norfloxacin used to be considered effective in SBP prevention, but in recent years its efficacy has been partially compromised by increasing quinolone-resistant bacteria. However, whether the effects of alternative prophylactic regimens are superior to norfloxacin remains controversial. The goal of this study is to compare the effects of norfloxacin with other antibiotics in SBP prophylaxis for cirrhotic patients. We systematically searched Pubmed, Embase, and Cochrane Library Databases. Two reviewers independently identified relevant random control trials (RCTs) comparing the role of norfloxacin and other antibiotics in SBP prevention. Eight studies comprising 1043 cirrhotic patients were included in this study. Norfloxacin and alternative antibiotics displayed comparable effects in SBP prophylaxis, survival benefit, overall infection prevention, and safety. Subgroup analyses revealed that rifaximin prophylaxis could reduce the recurrence of SBP with fewer adverse events but failed to improve overall survival compared with norfloxacin. Other antibiotics are a reasonable alternative to norfloxacin in the prophylaxis of SBP. Rifaximin prophylaxis could be an alternative choose of antibiotic for SBP prevention because of its better protective effect and safety.

Sections du résumé

BACKGROUND BACKGROUND
Spontaneous bacterial peritonitis (SBP) is a life-threatening complication in patients with advanced cirrhosis. Prophylactic Norfloxacin used to be considered effective in SBP prevention, but in recent years its efficacy has been partially compromised by increasing quinolone-resistant bacteria. However, whether the effects of alternative prophylactic regimens are superior to norfloxacin remains controversial. The goal of this study is to compare the effects of norfloxacin with other antibiotics in SBP prophylaxis for cirrhotic patients.
METHODS METHODS
We systematically searched Pubmed, Embase, and Cochrane Library Databases. Two reviewers independently identified relevant random control trials (RCTs) comparing the role of norfloxacin and other antibiotics in SBP prevention.
RESULTS RESULTS
Eight studies comprising 1043 cirrhotic patients were included in this study. Norfloxacin and alternative antibiotics displayed comparable effects in SBP prophylaxis, survival benefit, overall infection prevention, and safety. Subgroup analyses revealed that rifaximin prophylaxis could reduce the recurrence of SBP with fewer adverse events but failed to improve overall survival compared with norfloxacin.
CONCLUSIONS CONCLUSIONS
Other antibiotics are a reasonable alternative to norfloxacin in the prophylaxis of SBP. Rifaximin prophylaxis could be an alternative choose of antibiotic for SBP prevention because of its better protective effect and safety.

Identifiants

DOI: 10.1186/s12879-023-08557-6 PMID: 37641014 PMC: PMC10463656
pubmed: 37641014
doi: 10.1186/s12879-023-08557-6
pii: 10.1186/s12879-023-08557-6
pmc: PMC10463656
doi:

Substances chimiques

Norfloxacin N0F8P22L1P
Anti-Bacterial Agents 0
Rifaximin L36O5T016N
Quinolones 0

Types de publication

Meta-Analysis Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

557

Subventions

Organisme : Sichuan Province Science and Technology Support Program
ID : 2020YFS0239
Organisme : Sichuan Province Science and Technology Support Program
ID : 2022YFS0173

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

Liver Int. 2018 Feb;38(2):295-302
pubmed: 28834270
J Hepatol. 1998 Sep;29(3):430-6
pubmed: 9764990
Turk J Gastroenterol. 2015 Mar;26(2):163-9
pubmed: 25835116
Hepatol Int. 2018 Mar;12(2):181-190
pubmed: 29224053
Hepatology. 2013 Apr;57(4):1651-3
pubmed: 23463403
Hepatology. 1990 Oct;12(4 Pt 1):716-24
pubmed: 2210673
Eur J Gastroenterol Hepatol. 2016 Dec;28(12):1450-1454
pubmed: 27512927
Hepatology. 2012 May;55(5):1551-61
pubmed: 22183941
Gastroenterology. 2002 Apr;122(4):923-30
pubmed: 11910344
PLoS One. 2014 May 13;9(5):e96920
pubmed: 24824199
Hepatology. 2017 Feb;65(2):592-603
pubmed: 27775818
Clin Gastroenterol Hepatol. 2011 Mar;9(3):260-5
pubmed: 21145427
Arq Gastroenterol. 2018 Jan-Mar;55(1):23-27
pubmed: 29561972
Hepatology. 2021 Aug;74(2):1014-1048
pubmed: 33942342
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD004791
pubmed: 19370611
N Engl J Med. 2021 Jun 17;384(24):2317-2330
pubmed: 34133861
Am J Gastroenterol. 2019 Jul;114(7):1091-1100
pubmed: 31180922
Expert Rev Gastroenterol Hepatol. 2019 Aug;13(8):751-759
pubmed: 31304804
Gastroenterology. 2007 Sep;133(3):818-24
pubmed: 17854593
World J Hepatol. 2016 Feb 28;8(6):307-21
pubmed: 26962397
Dig Dis Sci. 2002 Jun;47(6):1356-61
pubmed: 12064813
J Hepatol. 2018 Aug;69(2):406-460
pubmed: 29653741
J Dig Dis. 2014 May;15(5):260-7
pubmed: 24612987
J Hepatol. 2016 Nov;65(5):1043-1054
pubmed: 27544545
Gastroenterology. 2019 Apr;156(5):1368-1380.e10
pubmed: 30552895
Can J Infect Dis. 1991 Winter;2(4):147-54
pubmed: 22529726
J Hepatol. 2014 Jan;60(1):197-209
pubmed: 23993913
Hepatol Int. 2016 Mar;10(2):377-85
pubmed: 26660707
Hepatology. 2016 Apr;63(4):1299-309
pubmed: 26084406
Liver Int. 2013 Aug;33(7):975-81
pubmed: 23522099
Gut. 2012 Feb;61(2):297-310
pubmed: 22147550
J Gastroenterol Hepatol. 2018 Jan;33(1):307-314
pubmed: 28671712
P T. 2009 Apr;34(4):204-10
pubmed: 19561863
Dig Dis. 2015;33(4):582-5
pubmed: 26159277
Hepatology. 2011 Aug;54(2):562-72
pubmed: 21574172
J Clin Exp Hepatol. 2022 Mar-Apr;12(2):336-342
pubmed: 35535057
Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):683-692
pubmed: 31107612
Arq Gastroenterol. 2005 Oct-Dec;42(4):256-62
pubmed: 16444382
Cochrane Database Syst Rev. 2020 Jan 16;1:CD013125
pubmed: 31978256
Am J Gastroenterol. 2018 Aug;113(8):1167-1176
pubmed: 29946179
Hepatol Int. 2020 May;14(3):399-413
pubmed: 32266675
Lancet. 2015 Oct 17;386(10003):1576-87
pubmed: 26423181
Gastroenterology. 2010 Oct;139(4):1246-56, 1256.e1-5
pubmed: 20558165
Hepatology. 1994 Dec;20(6):1495-501
pubmed: 7982650
Ann Hepatol. 2019 Sep - Oct;18(5):730-735
pubmed: 31175020
Clin Transl Gastroenterol. 2020 Aug;11(8):e00223
pubmed: 32955202

Auteurs

Shuailing Song (S)

Department of Gastroenterology, West China Hospital of Sichuan University, NO.37 GuoXue Street, Chengdu, 610041, Sichuan, China.

Yi Yang (Y)

Department of Laboratory Medicine, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Chong Geng (C)

Department of Gastroenterology, West China Hospital of Sichuan University, NO.37 GuoXue Street, Chengdu, 610041, Sichuan, China.
Laboratory of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Zeya Tang (Z)

Department of Outpatient, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Chunhui Wang (C)

Department of Gastroenterology, West China Hospital of Sichuan University, NO.37 GuoXue Street, Chengdu, 610041, Sichuan, China.

Xiao Li (X)

Department of Gastroenterology, West China Hospital of Sichuan University, NO.37 GuoXue Street, Chengdu, 610041, Sichuan, China. lixiao5166@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Norfloxacin versus alternative antibiotics for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Fluoroquinolones › Norfloxacine › Norfloxacin versus alternative antibiotics for...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Norfloxacin versus alternative antibiotics for...
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Rifamycine › Rifaximine › Norfloxacin versus alternative antibiotics for...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Fibrose › Cirrhose du foie › Norfloxacin versus alternative antibiotics for...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinoléines › Quinolinone › Norfloxacin versus alternative antibiotics for...